USA flag logo/image

An Official Website of the United States Government

The identification of novel negative allosteric modulators of the nicotinic…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93627
Program Year/Program:
2009 / STTR
Agency Tracking Number:
DA026245
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: The identification of novel negative allosteric modulators of the nicotinic recep
Agency: HHS
Contract: 1R41DA026245-01
Award Amount: $190,807.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma w ith the expertise of Professor Dennis McKay to identify novel and subtype selective negative allosteric modulators of the nicotinic acetylcholine receptor. We believe that such compounds could provide a significant improvement in available therapies for sm oking addiction. Work supported with this grant will examine the Promiliad Biopharma compound database to identify small molecules that fit a previously identifed nicotinic acetylcholine receptor pharmacophore. Compounds that fit the pharmacophore will be examined in a variety of pharmacological assays to identify negative allosteric modulators of three subtypes of the nicotinic acetylcholine receptor. In addition to the in silico screening of the Promiliad compound library, Promiliad Biopharma will prepare libraries of previously identified negative allosteric modulators of the nicotinic acetylcholine receptor. These libraries will make use of Promiliad's drug discovery technology in order to prepare a diverse and novel set of analogues. In addition to iden tifying a new selective negative allosteric modulator of the nicotinic acetylcholine receptor, this project will also allow Promilad to test the hypothesis that the Promiliad drug discovery technology can be used for the idenfication of a variety of therap eutic agents. PUBLIC HEALTH RELEVANCE: The goal of this Phase I STTR project is to identify novel negative allosteric modulators of the nicotinic acetylcholine receptor. This project seeks to partner the drug discovery technology of the Promiliad Biopharma with the expertise of Professor Dennis McKay to identify novel and subtype selective negative allosteric modulators of the nicotinic acetylcholine receptor. We believe that such compounds could provide a significant improvement in available therapies for smoking addiction.

Principal Investigator:

Dennis B. Mckay
6142923771
MCKAY.2@OSU.EDU

Business Contact:

Dana E. Warren
dana.e.warren@mail.promiliad.com
Small Business Information at Submission:

PROMILIAD BIOPHARMA, INC.
PROMILIAD BIOPHARMA, INC ALBERTON, MT 59820

EIN/Tax ID: 481284415
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
OHIO STATE UNIVERSITY
Office of Sponsored Programs
1960 Kenny Road
COLUMBUS, OH 43210-2340
RI Type: Nonprofit college or university